This drug is the 'breakthrough of the year' and it could mean the end of the HIV epidemicLenacapavir shows potential to nearly eliminate new HIV infections, marking a hopeful step toward resolving the HIV epidemic.
A twice-yearly shot of this drug could help end AIDS - 'it's unprecedented'The new HIV vaccine shows exceptional effectiveness and could significantly improve prevention efforts, especially for high-risk populations.
Gamechanger' HIV prevention drug to be made available cheaply in 120 countriesGilead has agreed to make lenacapavir available cheaply in 120 countries, but many high-HIV burden nations are excluded, creating access issues.
A twice-yearly shot could help end AIDS. But will it get to everyone who needs it?Gilead's lenacapavir shows exceptional efficacy in preventing HIV and is a potential game-changer in the global fight against AIDS.
HIV vaccine' could be made for just $40 a year for every patientLenacapavir, a new drug, could revolutionize HIV prevention if available affordably globally, priced at $40 a year instead of $42,250 currently.
This drug is the 'breakthrough of the year' and it could mean the end of the HIV epidemicLenacapavir shows potential to nearly eliminate new HIV infections, marking a hopeful step toward resolving the HIV epidemic.
A twice-yearly shot of this drug could help end AIDS - 'it's unprecedented'The new HIV vaccine shows exceptional effectiveness and could significantly improve prevention efforts, especially for high-risk populations.
Gamechanger' HIV prevention drug to be made available cheaply in 120 countriesGilead has agreed to make lenacapavir available cheaply in 120 countries, but many high-HIV burden nations are excluded, creating access issues.
A twice-yearly shot could help end AIDS. But will it get to everyone who needs it?Gilead's lenacapavir shows exceptional efficacy in preventing HIV and is a potential game-changer in the global fight against AIDS.
HIV vaccine' could be made for just $40 a year for every patientLenacapavir, a new drug, could revolutionize HIV prevention if available affordably globally, priced at $40 a year instead of $42,250 currently.
This preventive drug could be a 'game changer' in ending the HIV epidemicLenacapavir shows potential to significantly reduce new HIV infections, fostering optimism towards the goal of ending the epidemic by 2030.
Gilead Agrees to Allow Generic Version of Groundbreaking H.I.V. Shot in Poor CountriesGilead aims to broaden access to lenacapavir through generic production in low-income countries but excludes middle-income nations, highlighting healthcare disparities.
HIV prophylactic lenacapavir very safe and very expensive DW 11/29/2024Lenacapavir is a revolutionary antiretroviral drug achieving nearly 100% effectiveness for HIV prevention and treatment with just two injections yearly.
This preventive drug could be a 'game changer' in ending the HIV epidemicLenacapavir shows potential to significantly reduce new HIV infections, fostering optimism towards the goal of ending the epidemic by 2030.
Gilead Agrees to Allow Generic Version of Groundbreaking H.I.V. Shot in Poor CountriesGilead aims to broaden access to lenacapavir through generic production in low-income countries but excludes middle-income nations, highlighting healthcare disparities.
HIV prophylactic lenacapavir very safe and very expensive DW 11/29/2024Lenacapavir is a revolutionary antiretroviral drug achieving nearly 100% effectiveness for HIV prevention and treatment with just two injections yearly.
A new way to prevent HIV delivers dramatic results in trialLenacapavir injection proved more effective than daily PrEP pills, showing promise for HIV prevention among women in sub-Saharan Africa.
Twice-yearly injectable lenacapavir, an HIV-prevention drug, reduces risk by 96%Lenacapavir, a twice-yearly injectable, is shown to be more effective than Truvada in preventing HIV in recent clinical trials.
Experts say a twice-yearly injection that offers 100 percent protection against HIV is 'stunning'Twice-yearly shots for AIDS were 100 percent effective in preventing infections in women, with high potential for broader use as a preventative measure.
Doctor behind trial of HIV prevention drug recounts breakthrough momentA new HIV prevention drug, lenacapavir, showed 100% protection for women aged 16 to 25 in South Africa and Uganda.
Humanity is closer to stopping HIV, and the biggest obstacle is the price of the drug that will do itLenacapavir shows 100% efficacy in preventing HIV infections in women with simple administration.It is not a vaccine but highly effective, sparking enthusiasm in the fight against HIV.
Trial shows that shot taken twice a year very effective at preventing HIV in women - LGBTQ NationLenacapavir injections taken twice yearly show 100% efficacy in preventing HIV infections in women and girls.
A new way to prevent HIV delivers dramatic results in trialLenacapavir injection proved more effective than daily PrEP pills, showing promise for HIV prevention among women in sub-Saharan Africa.
Twice-yearly injectable lenacapavir, an HIV-prevention drug, reduces risk by 96%Lenacapavir, a twice-yearly injectable, is shown to be more effective than Truvada in preventing HIV in recent clinical trials.
Experts say a twice-yearly injection that offers 100 percent protection against HIV is 'stunning'Twice-yearly shots for AIDS were 100 percent effective in preventing infections in women, with high potential for broader use as a preventative measure.
Doctor behind trial of HIV prevention drug recounts breakthrough momentA new HIV prevention drug, lenacapavir, showed 100% protection for women aged 16 to 25 in South Africa and Uganda.
Humanity is closer to stopping HIV, and the biggest obstacle is the price of the drug that will do itLenacapavir shows 100% efficacy in preventing HIV infections in women with simple administration.It is not a vaccine but highly effective, sparking enthusiasm in the fight against HIV.
Trial shows that shot taken twice a year very effective at preventing HIV in women - LGBTQ NationLenacapavir injections taken twice yearly show 100% efficacy in preventing HIV infections in women and girls.
Beginning of end of HIV epidemic? - Harvard GazetteResearchers are cautiously optimistic about a new preventative treatment for the AIDS virus, lenacapavir, showing promising results in preventing infection.